The Quiet Revolution in Dialysis: A Living Vessel Nears US Approval

EINDHOVEN, The Netherlands – July 02, 2026 – In the high-stakes world of medical technology, true disruption often happens not with a bang, but with the quiet hum of cellular regeneration. This week, Dutch-American medtech firm Xeltis announced a pivotal moment in that quiet revolution: its US pivotal trial for the aXess™ vascular access device has surpassed 50% enrollment. While trial milestones can seem routine, this one represents a significant strategic advance for a technology poised to reshape the grueling reality for hundreds of thousands of patients with end-stage renal disease (ESRD).

The aXess device is not just another synthetic tube. It is a bioabsorbable implant designed to be a temporary scaffold that the body uses to build a new, completely natural, living blood vessel. For patients tethered to hemodialysis machines, whose lives are often punctuated by painful and dangerous access failures, this innovation isn’t just an incremental improvement—it’s a paradigm shift.

“Reaching this milestone reflects the strong momentum behind the aXess™ program as we advance towards FDA approval in the US,” said Shawn Gage, Vice President of US Clinical Affairs at Xeltis. The trial, which aims to enroll 140 patients across 20 US sites, is the final major hurdle before the device can be considered for the American market, a process accelerated by the FDA’s Breakthrough Device Designation granted in November 2024.

The High Stakes of Vascular Access

To understand the strategic importance of aXess™, one must first grasp the profound and often brutal limitations of current hemodialysis access methods. For the more than 800,000 Americans living with ESRD, reliable vascular access is not a convenience; it is their lifeline. Yet, this lifeline is notoriously fragile.

The “gold standard,” the arteriovenous (AV) fistula, is created by surgically connecting a patient’s own artery and vein. While it offers the lowest risk of infection, a significant percentage fail to mature properly, rendering them useless for dialysis. The next option, the arteriovenous graft (AVG), uses a synthetic tube—typically ePTFE—to connect the vessels. While faster to use, AVGs are plagued by complications. They have infection rates up to 10 times higher than fistulas and are prone to stenosis (narrowing) and thrombosis (clotting), leading to frequent and costly reinterventions to maintain blood flow.

At the bottom of the hierarchy are central venous catheters, which carry the highest risks of life-threatening bloodstream infections and can damage central veins, jeopardizing future access options. The cycle of access creation, failure, and revision creates a massive clinical and economic burden, accounting for a substantial portion of hospitalizations among dialysis patients and costing healthcare systems billions annually. This is the vulnerable landscape Xeltis aims to fundamentally alter.

A 'Living Vessel': The Strategic Rationale Behind Restorex™

Xeltis’s core strategy is built on its proprietary Restorex™ platform, a technology rooted in the concept of Endogenous Tissue Restoration (ETR). Instead of implanting a permanent foreign object, the aXess graft acts as an intelligent scaffold. Its porous, advanced polymer structure attracts the patient’s own cells, which infiltrate the device and begin to form new, native vessel tissue. Over a period of months, the synthetic scaffold is safely absorbed by the body, leaving behind a completely natural, living, and long-lasting blood vessel.

This approach is a direct strategic counter to the primary failure point of traditional synthetic grafts: the foreign body response. The body’s reaction to inert materials like ePTFE often leads to chronic inflammation and intimal hyperplasia—an overgrowth of cells that narrows the graft and leads to failure. By becoming living tissue, aXess aims to sidestep this entire cascade of complications.

Evidence for this strategy’s success is already robust. Data from the European pivotal trial, which supported the device’s CE mark approval, was compelling. It demonstrated a secondary patency rate significantly higher than the historical benchmark for conventional grafts, alongside lower reintervention rates and enhanced resistance to infection. These results suggest a more durable, reliable, and safer access solution, validating the company’s long-term vision.

Navigating the Path to the US Market

With European commercialization underway, the 50% enrollment milestone in the US trial marks a critical phase in Xeltis’s global strategy. The study is designed to prove the device’s efficacy in a complex, real-world patient population, a necessary step for securing FDA approval.

Dr. John Lucas III of Lucas Surgical Group, the trial’s National Principal Investigator, commented on the device’s potential: “aXess™ is a unique technology, and it is encouraging to see the continued progress of the study as we work to validate its promise in transforming the hemodialysis landscape.”

The patient experience is central to this validation. While clinical data measures patency and safety, the human impact is the ultimate metric of success. One patient participating in the US trial offered a powerful, unvarnished endorsement: “I love it! I recommend it to people now. The one that I have I feel like it works 100% satisfactory and I recommend it to people all the time!”

This sentiment underscores the deep-seated need for an option that not only works but feels like a part of the patient’s own body, free from the constant anxiety of failure. The trust and commitment of these trial participants are essential, as their experience will form the bedrock of the evidence presented to the FDA.

Reshaping the Renal Care Landscape

Should the US trial replicate the success seen in Europe, the implications for the renal care market will be profound. Xeltis would be positioned to challenge established players like Gore and BD, not by offering a slightly better synthetic graft, but by offering a completely different category of solution. For healthcare providers and payers, the economic calculus is clear: a device that significantly reduces reinterventions and infection-related hospitalizations promises substantial long-term cost savings, shifting spending from reactive complication management to proactive, durable care.

Given the relentlessly growing ESRD population, driven by epidemics of diabetes and hypertension, the demand for such an innovation is only intensifying. The progress of the aXess trial is therefore being watched closely by clinicians, investors, and competitors alike. For the hundreds of thousands of patients tethered to dialysis machines, the completion of this trial represents more than just a clinical data point; it signifies a potential new lease on a life less defined by their treatment.